Pacira BioSciences, Inc. (PCRX)

Market Cap	799.38M
Revenue (ttm)	690.31M
Net Income (ttm)	63.59M
Shares Out	46.13M
EPS (ttm)	1.28
PE Ratio	13.55
Forward PE	5.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	594,737
Open	17.30
Previous Close	17.49
Day's Range	17.00 - 17.56
52-Week Range	11.16 - 35.95
Beta	0.84
Analysts	Buy
Price Target	27.30 (+57.53%)
Earnings Date	Oct 31, 2024

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and sup...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 712
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Financial Performance

In 2023, Pacira BioSciences's revenue was $674.98 million, an increase of 1.22% compared to the previous year's $666.82 million. Earnings were $41.96 million, an increase of 163.72%.

Analyst Forecast

According to 10 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $27.3, which is an increase of 57.53% from the latest price.

Price Target

$27.3

(57.53% upside)

Analyst Consensus: Buy